Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

61.75 

0.05 0.1%

as of Sep 13 '19

52 Week Range:

49.01 65.79


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Akynzeo, and Aloxi; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, Bonviva, and Alfarol; renal diseases consist of Mircera, Oxarol and Epogin; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, Pegasys, Sigmart, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd.; and collaborative research agreement with Anaeropharma Science Inc. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding AG.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 5.38
5.78
7.42
8.23
7.49
6.98
7.28
8.53
9.39
9.14
10.66
growth rate 7.4% 28.4% 10.9% -9.0% -6.8% 4.3% 17.2% 10.1% -2.7% 16.6%
Earnings BIT 80,591.00
77,869.00
86,784.00
76,884.00
98,934.00
124,322.00
growth rate -3.4% 11.5% -11.4% 28.7% 25.7%
Avg.PE 37.60
37.48
33.60
40.01
growth rate -0.3% -10.4% 19.1%
ROA 8.38
11.11
7.90
6.77
8.60
7.92
7.10
8.01
6.73
8.77
10.44
growth rate 32.6% -28.9% -14.3% 27.0% -7.9% -10.4% 12.8% -16.0% 30.3% 19.0%
ROE 10.08
13.67
9.41
7.78
10.18
9.60
8.73
10.00
8.43
10.87
12.78
growth rate 35.6% -31.2% -17.3% 30.9% -5.7% -9.1% 14.6% -15.7% 28.9% 17.6%
ROIC 9.76
13.58
9.36
7.73
10.13
9.60
8.73
10.00
8.43
10.88
12.78
growth rate 39.1% -31.1% -17.4% 31.1% -5.2% -9.1% 14.6% -15.7% 29.1% 17.5%
Cur. Ratio 4.39
4.09
7.08
6.09
5.19
5.16
4.71
4.27
4.68
4.87
4.43
growth rate -6.8% 73.1% -14.0% -14.8% -0.6% -8.7% -9.3% 9.6% 4.1% -9.0%
Quick Ratio 3.06
2.79
4.57
4.05
3.62
3.71
3.41
2.97
3.02
3.39
3.17
growth rate -8.8% 63.8% -11.4% -10.6% 2.5% -8.1% -12.9% 1.7% 12.3% -6.5%
Leverage 1.21
1.25
1.13
1.17
1.20
1.22
1.24
1.26
1.25
1.23
1.22
growth rate 3.3% -9.6% 3.5% 2.6% 1.7% 1.6% 1.6% -0.8% -1.6% -0.8%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 119,989.00
128,387.00
159,887.00
158,717.00
167,483.00
175,001.00
179,559.00
growth rate 7.0% 24.5% -0.7% 5.5% 4.5% 2.6%
Acct.Payable 41,725.00
35,939.00
35,386.00
78,353.00
72,346.00
63,518.00
71,706.00
growth rate -13.9% -1.5% 121.4% -7.7% -12.2% 12.9%
Cur.Assets 475,695.00
504,235.00
538,904.00
567,773.00
578,760.00
599,141.00
600,093.00
growth rate 6.0% 6.9% 5.4% 1.9% 3.5% 0.2%
Total Assets 587,720.00
697,212.00
739,538.00
787,401.00
806,285.00
852,473.00
919,548.00
growth rate 18.6% 6.1% 6.5% 2.4% 5.7% 7.9%
Cash 110,935.00
115,070.00
114,037.00
101,707.00
95,368.00
139,074.00
146,860.00
growth rate 3.7% -0.9% -10.8% -6.2% 45.8% 5.6%
Inventory 108,893.00
128,536.00
139,571.00
161,135.00
185,440.00
169,056.00
159,360.00
growth rate 18.0% 8.6% 15.5% 15.1% -8.8% -5.7%
Cur.Liabilities 91,633.00
97,667.00
114,350.00
133,058.00
123,660.00
122,902.00
135,218.00
growth rate 6.6% 17.1% 16.4% -7.1% -0.6% 10.0%
Liabilities 97,646.00
124,008.00
141,782.00
160,130.00
159,788.00
159,576.00
163,020.00
growth rate 27.0% 14.3% 12.9% -0.2% -0.1% 2.2%
LT Debt 195.00
185.00
604.00
510.00
207.00
82.00
growth rate -5.1% 226.5% -15.6% -59.4% -60.4%
Equity 596,099.00
625,857.00
645,508.00
691,924.00
755,864.00
growth rate 5.0% 3.1% 7.2% 9.2%
Common Shares 545.00
545.00
544.00
544.00
544.00
545.00
546.00
547.00
547.00
547.00
548.00
growth rate 0.0% -0.2% 0.0% 0.0% 0.2% 0.2% 0.2% 0.0% 0.0% 0.2%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 15,053.00
11,587.00
16,232.00
18,367.00
30,084.00
32,881.00
71,785.00
growth rate -23.0% 40.1% 13.2% 63.8% 9.3% 118.3%
Cash Dividends 24,520.00
28,375.00
31,677.00
30,054.00
35,010.00
growth rate 15.7% 11.6% -5.1% 16.5%
Cash From OA 77,299.00
53,521.00
37,034.00
62,918.00
38,787.00
107,623.00
119,074.00
growth rate -30.8% -30.8% 69.9% -38.4% 177.5% 10.6%
FCF per Share 0.53
0.19
0.58
1.44
0.84
0.74
0.25
0.68
0.07
0.29
1.32
growth rate -64.2% 205.3% 148.3% -41.7% -11.9% -66.2% 172.0% -89.7% 314.3% 355.2%
Sale Purchase of Stock 1,226.00
1,406.00
506.00
922.00
growth rate 14.7% -64.0% 82.2%
FCF 14,054.00
66,461.00
15,572.00
69,593.00
77,299.00
38,557.00
17,867.00
37,655.00
2,365.00
63,097.00
41,403.00
growth rate 372.9% -76.6% 346.9% 11.1% -50.1% -53.7% 110.8% -93.7% 2,568.0% -34.4%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 391,220.00
423,652.00
461,109.00
498,839.00
491,780.00
534,199.00
579,787.00
growth rate 8.3% 8.8% 8.2% -1.4% 8.6% 8.5%
Op.Income 48,991.00
80,591.00
77,869.00
86,784.00
76,884.00
98,934.00
124,322.00
growth rate 64.5% -3.4% 11.5% -11.4% 28.7% 25.7%
IBT 76,164.00
87,276.00
74,448.00
97,030.00
121,449.00
growth rate 14.6% -14.7% 30.3% 25.2%
Net Income 48,991.00
50,895.00
50,980.00
61,125.00
53,592.00
72,713.00
92,488.00
growth rate 3.9% 0.2% 19.9% -12.3% 35.7% 27.2%
EPS 72.04
103.98
76.12
64.73
84.58
93.35
93.38
111.79
97.97
132.83
168.80
growth rate 44.3% -26.8% -15.0% 30.7% 10.4% 0.0% 19.7% -12.4% 35.6% 27.1%
Gross Profit 223,494.00
236,863.00
244,149.00
258,601.00
243,836.00
280,028.00
316,940.00
growth rate 6.0% 3.1% 5.9% -5.7% 14.8% 13.2%
R&D 80,625.00
83,799.00
85,011.00
92,947.00
99,202.00
growth rate 3.9% 1.5% 9.3% 6.7%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 28,207.00
31,344.00
26,410.00
46,094.00
48,959.00
growth rate 11.1% -15.7% 74.5% 6.2%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 162,834.00
172,037.00
179,559.00
175,874.00
189,828.00
growth rate 5.7% 4.4% -2.1% 7.9%
Acct.Payable 70,351.00
72,977.00
71,706.00
77,421.00
90,856.00
growth rate 3.7% -1.7% 8.0% 17.4%
Cur.Assets 622,924.00
620,971.00
600,093.00
598,889.00
634,246.00
growth rate -0.3% -3.4% -0.2% 5.9%
Total Assets 873,347.00
890,843.00
919,548.00
932,242.00
986,620.00
growth rate 2.0% 3.2% 1.4% 5.8%
Cash 154,599.00
145,977.00
146,860.00
125,818.00
149,165.00
growth rate -5.6% 0.6% -14.3% 18.6%
Inventory 169,999.00
163,841.00
159,360.00
168,728.00
167,692.00
growth rate -3.6% -2.7% 5.9% -0.6%
Cur.Liabilities 119,811.00
128,352.00
135,218.00
136,523.00
159,588.00
growth rate 7.1% 5.4% 1.0% 16.9%
Liabilities 141,688.00
151,195.00
163,020.00
171,778.00
194,455.00
growth rate 6.7% 7.8% 5.4% 13.2%
LT Debt 147.00
114.00
200.00
growth rate -22.5% 75.4%
Equity 731,174.00
738,977.00
755,864.00
760,464.00
792,165.00
growth rate 1.1% 2.3% 0.6% 4.2%
Common Shares 72,995.00
72,995.00
73,000.00
73,012.00
73,012.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 5,227.00
8,690.00
47,977.00
7,370.00
2,741.00
growth rate 66.3% 452.1% -84.6% -62.8%
Cash Dividends 106.00
16,853.00
110.00
29,923.00
170.00
growth rate 15,799.1% -99.4% 27,102.7% -99.4%
Cash From OA 14,610.00
21,418.00
32,241.00
33,040.00
32,256.00
growth rate 46.6% 50.5% 2.5% -2.4%
Sale Purchase of Stock 383.00
growth rate
FCF 9,383.00
12,728.00
-15,736.00
25,670.00
29,515.00
growth rate 35.7% -100.0% 100.0% 15.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 137,695.00
141,318.00
153,347.00
154,288.00
165,997.00
growth rate 2.6% 8.5% 0.6% 7.6%
Op.Income 28,207.00
31,344.00
26,410.00
46,094.00
48,959.00
growth rate 11.1% -15.7% 74.5% 6.2%
IBT 27,343.00
30,636.00
25,817.00
45,421.00
48,360.00
growth rate 12.0% -15.7% 75.9% 6.5%
Net Income 20,785.00
21,668.00
22,148.00
35,031.00
34,224.00
growth rate 4.3% 2.2% 58.2% -2.3%
Gross Profit 72,456.00
75,374.00
85,513.00
90,380.00
101,925.00
growth rate 4.0% 13.5% 5.7% 12.8%
R&D 23,481.00
22,349.00
28,320.00
25,139.00
26,683.00
growth rate -4.8% 26.7% -11.2% 6.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (68.05)

YOY Growth Grade:

D (42.46)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 45.71 43.39
EPS / Growth 1.42

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 7.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 7.5% 7.5% 7.5%
Future PE 0.01 7.53 7.53
Future EPS 2.94 2.94 2.94
Value Price
MOS %
0.01
-100.0%
5.47
-91.1%
5.47
-91.1%
MOS Price 0.00 2.73 2.73
IRT 19.23 19.23 19.23

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.